CLINIQ

Vetted Research Clinic

CLINIQ

✓ VettedSince 2026-07-01

Research reference only. Research reference only. Clinic listings are for informational purposes. ResearchRelay does not endorse or recommend any clinic for personal use. Always consult a qualified healthcare professional.

About

CLINIQ is a vetted research clinic publishing structured peptide protocols for educational and research reference. Their work spans pre-surgical metabolic preparation, systemic tissue repair, mitochondrial longevity, GH axis support, and visceral adipose reduction. All protocols are published for research reference only.

Business Information

Legal Entity	—
Registration	—
Address	—
Country	—
Email	—
Website	—
Phone	—

Location

Research reference only. All protocols published by CLINIQ are for informational and educational purposes only. Nothing here constitutes medical advice. Not intended for human use. Consult a qualified healthcare professional before considering any compound.

Tri-receptor GLP-1/GIP/glucagon agonism for adipose tissue reduction and metabolic recalibration prior to elective procedures. Retatrutide is the primary compound. Combination support compounds are included to maintain muscle mass, hydration, and digestive function throughout the dose escalation sequence.

Retatrutide — Dose Escalation Schedule12-Week Protocol

Phase	Duration	Schedule	Dose	Weekly Total
Ramp-up	Week 1	Mon + Thu on wake	0.25mg	0.5mg
Escalation I	Weeks 2–3	2× per week	0.5mg	1mg
Escalation II	Weeks 4–5	Mon / Wed / Fri	0.5mg	1.5mg
Escalation III	Weeks 6–7	Mon + Thu	1mg	2mg
Peak	Weeks 8–9	Mon / Wed / Fri	1mg	3mg
Taper I	Week 10	Mon + Thu	1mg	2mg
Taper II	Week 11	Mon + Thu	0.5mg	1mg
Taper III	Week 12	Mon + Thu	0.25mg	0.5mg

Combination Support Protocol

The following are required throughout the Retatrutide cycle to maintain muscle mass, electrolyte balance, and digestive motility under GLP-1 receptor agonism:

Hydration — 3–4 litres of water daily. GLP-1 agonism reduces thirst signalling; active hydration is required.
Electrolytes — Daily supplementation to compensate for increased urinary excretion at elevated hydration volumes.
Creatine — 5g daily throughout. Maintains phosphocreatine pools and supports lean mass retention during caloric restriction.
Dietary carbohydrate and fibre — Maintain adequate intake to sustain digestive motility, which is reduced by GLP-1 receptor agonism.
Morning protocol — Water with apple cider vinegar upon waking, prior to first injection.

Connective tissue repair, extracellular matrix remodelling, angiogenic pathway activation, and collagen synthesis upregulation. Research applications include musculoskeletal recovery, dermal structural repair, and growth factor-mediated tissue regeneration. This protocol references the CLINIQ modification of the ResearchRelay injury healing protocol.

Base protocol: This follows the same three-phase structure as the ResearchRelay Injury Healing Protocol with two CLINIQ-specific modifications applied below.

CLINIQ Modifications to Base ProtocolBoth changes applied simultaneously

Parameter	Base Protocol	CLINIQ Protocol
KLOW mix daily dose	10iu daily	12iu daily
KLOW schedule	Daily, uninterrupted	5 days on / 2 days off

All other parameters — localised BPC-157 timing, TB-500 acute blast in Month 1, BAC water reconstitution ratios, and 3-month duration — remain identical to the base protocol.

Three-compound sequential protocol targeting mitochondrial electron transport chain efficiency, metabolic signalling via AMPK/PGC-1α, and circadian rhythm entrainment. Mirrors the ResearchRelay mitochondrial protocol with CLINIQ-specific sequencing.

Compound reference: For detailed mechanism documentation on SS-31, MOTS-C, and Epitalon, see the ResearchRelay Mitochondrial Protocol.

Phase 1 — SS-31 SoloMonth 1 · Mon–Fri

Compound	Dose	Schedule	Duration
SS-31	1mg	Monday to Friday	4 weeks

Phase 2 — SS-31 + MOTS-CMonths 2–3 · Mon–Fri

Compound	Dose	Schedule	Duration
SS-31	0.5mg	Monday to Friday	8 weeks
MOTS-C	0.5mg	Monday to Friday (same injection)	8 weeks

Phase 3 — Epitalon OverlayFinal 20 Days of Month 3 · Nightly

Compound	Dose	Timing	Duration
Epitalon	5mg	Every evening — consistent timing required for circadian reset	20 days

SS-31 + MOTS-C continue Mon–Fri during this phase. Epitalon is added as a nightly overlay. The 20-day cycle length is fixed — extending it is unsupported by the research literature.

Endogenous growth hormone pulse amplification via combined GHRP/GHRH receptor agonism. Research applications: lean mass accretion, body composition remodelling, anabolic recovery support, and slow-wave sleep architecture enhancement. Combinable with Protocols 1, 2, and 3 — except during the Epitalon phase of Protocol 3.

Timing critical. Administer at least 2 hours after last meal. If running concurrently with Protocol 1 (Retatrutide), allow 4 hours after last meal — GLP-1 agonism slows gastric emptying and insulin clearance, extending the required fasting window.

Ipamorelin × CJC-1295 — Dose Schedule12-Week Protocol · Before Sleep · Mon–Fri

Phase	Duration	Dose (each compound)	Schedule
Ramp-up	Weeks 1–2	0.125mg	Mon–Fri before sleep
Maintenance	Weeks 3–10	0.25mg	Mon–Fri before sleep
Taper	Weeks 11–12	0.125mg	Mon–Fri before sleep

GHRH receptor agonism via Tesamorelin for selective visceral fat reduction independent of total body weight changes. Works via IGF-1 modulation. Documented in clinical research. Synergistic with Protocol 1 (Retatrutide) and the KLOW mix — Tesamorelin targets visceral adipose specifically while Retatrutide drives broader metabolic recalibration.

Tesamorelin — Dose Schedule12-Week Protocol · Mon–Fri

Phase	Duration	Dose	Schedule
Ramp-up	Weeks 1–2	0.25mg	Mon–Fri
Escalation I	Weeks 3–4	0.5mg	Mon–Fri
Escalation II	Weeks 5–6	0.75mg	Mon–Fri
Maintenance	Weeks 7–12	1mg	Mon–Fri

Custom combinations: CLINIQ publishes additional protocols and combination stacks beyond those listed here. For custom protocol discussion or clinic-specific guidance, contact CLINIQ directly.